Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Dietary Management

- PMLiVE

Cuttsy+Cuttsy retains IPA gold standard in CPD

Staff investment recognised by the Institute of Practitioners in Advertising

- PMLiVE

Braille Smartwatch among D&AD Black Pencil recipients

Paralympic work also picks up the awards' highest accolade

Taking an integrated approach to research

Director Melinda Shorr and Associate Director Steven Helm discuss the benefits of integrated research techniques.Watch the video: http://bit.ly/2qF0qO2

Inizio

Online Community Research

What to consider when running an online research community?

Inizio

- PMLiVE

Shire licences Parion dry eye drug in $535m deal

Bolsters the Irish group's ophthalmic portfolio

- PMLiVE

Real-world evidence: It’s all in the approach

The merit of real-world evidence in the promotion and use of medicines is increasing and so too are the number of methodologies available

- PMLiVE

Medtronic integrates Garmin data into its remote monitoring platform

Can now sync information from vivofit wearable devices

The simple test for great pharma digital communication

What do great life science digital communications look like? Try asking yourself this simple question and see how well your e-detailing and multichannel communications match up.

Anthill Agency

Research Partnership appoints Helen Parfitt as Director, Head of Therapy Watch

Helen Parfitt has joined Research Partnership as Head of Therapy Watch at the company’s global head office in London. Therapy Watch is a ‘real-time’ syndicated global market tracking tool that...

Inizio

Research Partnership is expanding its US capabilities with new offices opening in San Francisco and New York

Research Partnership is today expanding its US operations across both the West and East Coast. Director Tom Winter has relocated from London and is today opening a new office in...

Inizio

AstraZeneca AZ

AZ gets first OK for PD-L1 inhibitor durvalumab

US regulators also approve Roche’s Ventana

- PMLiVE

Takeda’s gamble on Ariad pays off with Alunbrig approval

ALK-inhibitor will treat NSCLC patients as second-line therapy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links